Patient Resources / About Radiotherapeutics

A more targeted kind of radiation.

If you or someone you love is facing cancer in the brain or spinal cord, “radiotherapeutic” may be a new word. It’s radiation that travels directly to the tumor, so less reaches healthy tissue nearby.

A different way in.

Radiation usually reaches a tumor from outside the body, passing through healthy tissue on the way. A targeted radiotherapeutic starts at the tumor itself, which changes how it’s given and how it’s being studied.

Instead of aiming radiation at a tumor from outside the body, a radiotherapeutic delivers it from within, right at the tumor. Cerenome’s radiotherapeutics use a form of the element rhenium (rhenium-186), which does two things at once:

Beta energy

Treats the tumor. Rhenium-186 releases beta energy that travels only about a millimeter or two. That short range concentrates the treatment on the tumor while limiting the dose to the healthy tissue around it.

Gamma energy

Lets the team watch in real time. It also releases gamma energy that can be imaged during treatment. The care team can see where the radiation went, rather than assuming.

What that can mean for you

Affecting less healthy tissue may mean fewer side effects, which is an important part of quality of life during treatment. These treatments and their benefits are still being studied.

Vs. chemotherapy

Chemotherapy travels through the whole body. A targeted radiotherapeutic is designed to concentrate at the tumor.

Vs. traditional radiation

Very low doses of external radiation pass through healthy tissue to reach a tumor. A targeted radiotherapeutic works from inside, at the tumor, so it doesn’t have to.

Treating CNS Cancers

Why getting there is the hard part.

These are the challenges targeted radiotherapeutics are designed to work around.

A natural barrier.

The blood-brain barrier protects the central nervous system (CNS), but it can also limit cancer treatments from reaching CNS tumors at therapeutically effective concentrations.

A sensitive target.

Healthy brain tissue is sensitive to radiation, which can limit the dose of external beam radiation that can be safely delivered to CNS tumors.

Hard to reach.

Tumors deep within the brain, or cancer that spreads through the cerebrospinal fluid (CSF), can be difficult to treat effectively with conventional therapies.

How Cerenome is working on it.

Cerenome’s targeted radiotherapeutic, REYOBIQ™—an investigational treatment—is being studied in clinical trials called ReSPECT™, in recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer. How it’s given depends on the cancer: either directly into the tumor with a method known as convection-enhanced delivery (CED) or into the CSF via an Ommaya reservoir, in an inpatient or outpatient setting depending on the tumor type.

These are investigational uses. The treatment is still being studied, and its safety and effectiveness have not been established. Your care team is the best guide to whether a clinical trial may be right for you.

Support & Resources

Where to learn more.

Questions to ask your care team
  • Could a targeted radiotherapy trial be an option for my diagnosis?
  • What would taking part involve, and what are the possible risks and benefits for me?
  • How would the treatment be given, and what should I expect?
Where to find support